These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 23001704

  • 1. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM.
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [Abstract] [Full Text] [Related]

  • 2. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M.
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M.
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N, Abdelsayed S, Veve M, Miller CD.
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [Abstract] [Full Text] [Related]

  • 11. Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers.
    Blonk M, Colbers A, Poirters A, Schouwenberg B, Burger D.
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5070-5. PubMed ID: 22802250
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
    Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.
    Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, Sherman KE, Butt AA, ACTG A5309s study team.
    Drugs R D; 2017 Dec; 17(4):557-567. PubMed ID: 28875397
    [Abstract] [Full Text] [Related]

  • 17. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E.
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [Abstract] [Full Text] [Related]

  • 18. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
    Hernández-Novoa B, Moreno A, Pérez-Elías MJ, Quereda C, Dronda F, Casado JL, Madrid-Elena N, Aguilar M, Fumero E, Moltó J, Moreno S.
    J Antimicrob Chemother; 2014 Feb; 69(2):471-5. PubMed ID: 24097843
    [Abstract] [Full Text] [Related]

  • 19. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.
    Joseph D, Rose P, Strelkowa N, Schultz A, Garcia J, Elgadi M, Huang F.
    J Clin Pharmacol; 2015 Apr; 55(4):384-91. PubMed ID: 25352040
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study.
    Cattaneo D, Cossu MV, Fucile S, Riva A, Baldelli S, Meraviglia P, Landonio S, Impagnatiello C, Resnati C, Galli M, Clementi E, Capetti A, Rizzardini G, Gervasoni C.
    Ther Drug Monit; 2015 Feb; 37(1):119-25. PubMed ID: 24988438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.